Cytokinetics Ownership | Who Owns Cytokinetics?


OverviewForecastRevenueFinancialsChartTranscripts

Cytokinetics Ownership Summary


Cytokinetics is owned by 13.64% institutional investors, 0.77% insiders, and 85.60% retail investors. Blackrock is the largest institutional shareholder, holding 14.40% of CYTK shares. Vanguard Health Care Inv is the top mutual fund, with 3.41% of its assets in Cytokinetics shares.

CYTK Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCytokinetics13.64%0.77%85.60%
SectorHealthcare Stocks 279.42%10.64%-190.05%
IndustryBiotech Stocks 64.05%10.69%25.27%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock14.67M14.40%$794.97M
Blackrock funding, inc. /de15.47M13.14%$727.68M
Vanguard group11.92M10.13%$560.52M
Fmr10.79M9.17%$507.78M
T. rowe price investment management10.75M9.14%$505.78M
Wellington management group llp7.89M6.70%$371.08M
State street6.17M5.24%$290.11M
Deep track capital, lp3.07M2.59%$123.54M
Geode capital management2.84M2.41%$133.69M
Rtw investments, lp2.72M2.30%$109.36M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Rp management980.39K22.73%$51.76M
Sarissa capital management lp833.80K12.15%$39.22M
Great point partners370.00K7.88%$14.87M
Vestal point capital, lp2.59M7.43%$104.11M
Boxer capital2.10M5.99%$113.78M
Superstring capital management lp129.39K5.27%$6.09M
Melqart asset management (uk)999.45K5.24%$40.17M
Dafna capital management398.10K4.54%$16.00M
Allostery investments lp70.00K4.06%$2.81M
Integral health asset management1.00M4.01%$47.04M

Top Buyers

HolderShares% AssetsChange
Blackrock14.67M0.02%2.26M
Capital investors1.10M0.01%1.10M
T. rowe price investment management10.75M0.31%1.06M
Norges bank989.72K0.01%989.72K
Ubs group1.20M0.01%888.44K

Top Sellers

HolderShares% AssetsChange
Darwin global management---4.58M
Pfm health sciences, lp---1.76M
Westfield capital management co lp---1.31M
Fmr10.79M0.03%-1.30M
Hood river capital management---1.26M

New Positions

HolderShares% AssetsChangeValue
Capital investors1.10M0.01%1.10M$51.56M
Norges bank989.72K0.01%989.72K$46.56M
Paradigm biocapital advisors lp858.66K1.58%858.66K$34.51M
Groupama asset managment350.00K0.01%350.00K$421.29K
Cutter capital management, lp175.00K3.06%175.00K$7.03M

Sold Out

HolderChange
True wealth design-1.00
New england capital financial advisors-1.00
Financial gravity asset management-2.00
Financial management professionals-5.00
American capital advisory-5.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202525-93.40%16,158,180-87.73%130.11%15-91.28%5-96.09%
Dec 31, 2024374-5.32%131,318,059-2.91%1110.84%166-12.17%12829.29%
Sep 30, 20243900.52%135,010,879-0.29%1140.65%187-6.50%99-2.94%
Jun 30, 2024388-14.35%135,400,42216.07%1321.01%200-11.11%102-22.14%
Mar 31, 20244536.34%116,652,8862.18%1140.82%22510.29%13111.02%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv4.07M3.41%-
iShares Core S&P Mid-Cap ETF3.89M3.25%-6.99K
Vanguard Total Stock Mkt Idx Inv3.80M3.18%16.51K
Vanguard US Total Market Shares ETF3.75M3.15%128.42K
Vanguard Small Cap Index2.92M2.44%-58.37K
iShares Russell 2000 ETF2.75M2.30%-52.19K
T. Rowe Price Capital Appreciation2.44M2.04%41.02K
T. Rowe Price Mid-Cap Growth2.25M1.88%268.00K
T. Rowe Price US Mid-Cap Growth Equity2.25M1.88%267.30K
T. Rowe Price Small-Cap Value2.10M1.76%288.91K

Recent Insider Transactions


DateNameRoleActivityValue
Aug 05, 2025Malik Fady Ibraham EVP Research & DevelopmentSell$72.68K
Jul 29, 2025Blum Robert I President & CEOSell$182.25K
Jul 22, 2025Malik Fady Ibraham EVP Research & DevelopmentSell$74.94K
Jul 14, 2025Blum Robert I President & CEOSell$190.75K
Jul 08, 2025Malik Fady Ibraham EVP Research & DevelopmentSell$67.52K

Insider Transactions Trends


DateBuySell
2025 Q3-6
2025 Q2-19
2025 Q1-22
2024 Q4-20
2024 Q3-25

CYTK Ownership FAQ


Who Owns Cytokinetics?

Cytokinetics shareholders are primarily institutional investors at 13.64%, followed by 0.77% insiders and 85.59% retail investors. The average institutional ownership in Cytokinetics's industry, Biotech Stocks , is 64.05%, which Cytokinetics falls below.

Who owns the most shares of Cytokinetics?

Cytokinetics’s largest shareholders are Blackrock (14.67M shares, 14.40%), Blackrock funding, inc. /de (15.47M shares, 13.14%), and Vanguard group (11.92M shares, 10.13%). Together, they hold 37.67% of Cytokinetics’s total shares outstanding.

Does Blackrock own Cytokinetics?

Yes, BlackRock owns 14.40% of Cytokinetics, totaling 14.67M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 794.97M$. In the last quarter, BlackRock increased its holdings by 2.26M shares, a 18.19% change.

Who is Cytokinetics’s biggest shareholder by percentage of total assets invested?

Rp management is Cytokinetics’s biggest shareholder by percentage of total assets invested, with 22.73% of its assets in 980.39K Cytokinetics shares, valued at 51.76M$.

Who is the top mutual fund holder of Cytokinetics shares?

Vanguard Health Care Inv is the top mutual fund holder of Cytokinetics shares, with 3.41% of its total shares outstanding invested in 4.07M Cytokinetics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools